Page last updated: 2024-11-12

marizomib

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

marizomib: a proteasome inhibitor from a marine bacterium Salinospora; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11347535
CHEMBL ID371405
CHEBI ID48045
SCHEMBL ID151667
MeSH IDM0452056

Synonyms (39)

Synonym
(1r,4r,5s)-4-(2-chloroethyl)-1-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
marizomibum
ml 858
(1r,4r,5s)-4-(2-chloroethyl)-1-[(s)-(1s)-cyclohex-2-en-1-yl(hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
marizomib
437742-34-2
npi 0052
(-)-salinosporamide a
npi-0052
CHEBI:48045 ,
salinosporamide a ,
CHEMBL371405
D09640
marizomib (usan/inn)
unii-703p9ydp7f
marizomib [usan:inn]
homosalinosporamide a
6-oxa-2-azabicyclo(3.2.0)heptane-3,7-dione, 4-(2-chloroethyl)-1-((s)-(1s)-2-cyclohexen-1-ylhydroxymethyl)-5-methyl-, (1r,4r,5s)-
703p9ydp7f ,
bdbm50398608
(1r,4r,5s)-4-(2-chloroethyl)-1-((s)-((1s)-cyclohex-2-en-1-yl)hydroxymethyl)-5-methyl- 6-oxa-2-azabicyclo(3.2.0)heptane-3,7-dione
6-oxa-2-azabicyclo(3.2.0)heptane-3,7-dione, 4-(2-chloroethyl)-1-((s)-(1s)-2-cyclohexen-1-ylhydroxymethyl)-5-methyl-, (1r,4r,5s)-
salinosporamide a [mi]
marizomib [inn]
marizomib [who-dd]
marizomib [usan]
NGWSFRIPKNWYAO-SHTIJGAHSA-N
SCHEMBL151667
AKOS027323566
CS-0002986
HY-10985
DB11762
DTXSID00904019
Q7404722
(1r,4r,5s)-4-(2-chloroethyl)-1-[(s)-[(1s)-cyclohex-2-en-1-yl]-hydroxymethyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
(1r,4r,5s)-4-(2-chloroethyl)-1-((s)-((s)-cyclohex-2-en-1-yl)(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
salinosporamide a;npi-0052
EX-A3259
A872651

Research Excerpts

Overview

Marizomib (MRZ) is a novel, irreversible proteasome inhibitor in clinical development for the treatment of relapsed or relapsed and refractory multiple myeloma (RRMM) It is a second-generation, irreversible procesome inhibitor with a more lipophilic structure.

ExcerptReferenceRelevance
"Marizomib is a second-generation, irreversible proteasome inhibitor with a more lipophilic structure that suggests the potential for penetrating the blood-brain barrier."( Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
Abraham, V; Bota, DA; Burrows, FJ; Desjardins, A; Di, K; Lloyd, GK; MacLaren, A; Trikha, M, 2016
)
2.6
"Marizomib (MRZ) is a novel, irreversible proteasome inhibitor in clinical development for the treatment of relapsed or relapsed and refractory multiple myeloma (RRMM). "( Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Anderson, KC; Chanan-Khan, AA; Chauhan, D; Hofmeister, CC; Jakubowiak, AJ; Kaufman, JL; Laubach, JP; Reich, S; Richardson, PG; Talpaz, M; Trikha, M; Zimmerman, TM, 2016
)
2.22
"Marizomib (NPI-0052) is an irreversible proteasome inhibitor, derived from a marine actinomycete, with activity and specificity that is distinct from other proteasome inhibitors."( Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
Cannell, PK; Harrison, SJ; Mainwaring, P; Millward, MJ; Padrik, P; Price, T; Reich, SD; Spencer, A; Trikha, M; Underhill, CR, 2016
)
2.18
"Marizomib (NPI-0052) is a naturally derived irreversible proteasome inhibitor that potently induces apoptosis via a caspase-8 and ROS-dependent mechanism in leukemia cells. "( Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs.
Chandra, J; Debose, L; Hale, R; Macherla, VR; Manton, CA; Miller, CP; Palladino, MA; Potts, BC, 2011
)
2.04

Effects

ExcerptReferenceRelevance
"Marizomib has a short half-life (<30 minutes), with high volume of distribution (∼15-416 L) and clearance (∼0.9-22 L/minutes)."( Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
Cannell, PK; Harrison, SJ; Mainwaring, P; Millward, MJ; Padrik, P; Price, T; Reich, SD; Spencer, A; Trikha, M; Underhill, CR, 2016
)
1.46
"Marizomib has been termed as orphan drug against multiple myeloma by US Food and Drug Administration (FDA) in 2013 and by European Medicines Agency (EMA) in 2014."( Marizomib, a potent second generation proteasome inhibitor from natural origin.
Diao, A; Ma, L, 2015
)
2.58

Pharmacokinetics

ExcerptReferenceRelevance
" Here we performed pharmacodynamic (PD) studies of NPI-0052 using human MM xenograft murine model."( Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
Anderson, KC; Chauhan, D; Lloyd, GK; Palladino, MA; Potts, BC; Singh, AV, 2010
)
0.59

Compound-Compound Interactions

ExcerptReferenceRelevance
" These effects of NPI-0052, alone and in combination with HDACi, warrant further testing to determine the compound's clinical efficacy in leukemia."( NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.
Ban, K; Chandra, J; Dujka, ME; McConkey, DJ; Miller, CP; Munsell, M; Palladino, M, 2007
)
0.34
" Other research groups showed that histone deacetylase inhibitors (valproic acid or benzamide derivative MS-275) in combination with NPI-0052 or PR-171 induced greater levels of acute leukemia cell death than in combination with bortezomib."( Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Fuchs, O; Kuzelova, K; Marinov, I; Provaznikova, D; Spicka, I, 2009
)
0.35
" They are administered individually or in combination with other regimens, to prevent severe side effects and resistance development."( Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice.
Bullova, P; Cougnoux, A; Kopacek, J; Marzouca, G; Pacak, K, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
"Phase I study (NPI-0052-102) evaluated the MTD, pharmacokinetics, and pharmacodynamics of marizomib intravenously on two dosing schedules."( Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
Cannell, PK; Harrison, SJ; Mainwaring, P; Millward, MJ; Padrik, P; Price, T; Reich, SD; Spencer, A; Trikha, M; Underhill, CR, 2016
)
0.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
proteasome inhibitorA drug that blocks the action of proteasomes, cellular complexes that break down proteins.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
salinosporamideFamily of cytotoxic secondary metabolites produced by the marine actinomycete Salinispora tropica.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
organic heterobicyclic compound
beta-lactone
gamma-lactamA lactam in which the amide bond is contained within a five-membered ring, which includes the amide nitrogen and the carbonyl carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
salinosporamide A biosynthesis1129

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency0.02940.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency0.02940.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Proteasome subunit beta type-11Homo sapiens (human)IC50 (µMol)0.00130.00130.70995.0000AID1853759
Proteasome subunit alpha type-7Homo sapiens (human)IC50 (µMol)0.00130.00130.70995.0000AID1853759
Proteasome subunit beta type-1Homo sapiens (human)IC50 (µMol)0.14400.00060.73766.3700AID1604182; AID1853759; AID706736
Proteasome subunit alpha type-1Homo sapiens (human)IC50 (µMol)0.00130.00130.70995.0000AID1853759
Proteasome subunit alpha type-2Homo sapiens (human)IC50 (µMol)0.00130.00130.70995.0000AID1853759
Proteasome subunit alpha type-3Homo sapiens (human)IC50 (µMol)0.00130.00130.70995.0000AID1853759
Proteasome subunit alpha type-4Homo sapiens (human)IC50 (µMol)0.00130.00130.70995.0000AID1853759
Proteasome subunit beta type-8Homo sapiens (human)IC50 (µMol)0.00130.00130.36985.0000AID1853759
Proteasome subunit beta type-9Homo sapiens (human)IC50 (µMol)0.00130.00100.76115.0000AID1853759
Proteasome subunit alpha type-5Homo sapiens (human)IC50 (µMol)0.00130.00130.70995.0000AID1853759
Proteasome subunit beta type-4Homo sapiens (human)IC50 (µMol)0.00130.00130.70995.0000AID1853759
Proteasome subunit beta type-6Homo sapiens (human)IC50 (µMol)0.00130.00130.69125.0000AID1853759
Proteasome subunit beta type-5Homo sapiens (human)IC50 (µMol)0.00760.00050.939410.0000AID1059479; AID1604186; AID1853759; AID706738
Proteasome subunit beta type-10Homo sapiens (human)IC50 (µMol)0.00130.00130.81515.0000AID1853759
Proteasome subunit beta type-3Homo sapiens (human)IC50 (µMol)0.00130.00130.70995.0000AID1853759
Proteasome subunit beta type-2Homo sapiens (human)IC50 (µMol)0.01330.00131.39067.9540AID1604184; AID1853759; AID706737
Proteasome subunit alpha type-6Homo sapiens (human)IC50 (µMol)0.00130.00130.70995.0000AID1853759
Proteasome subunit alpha-type 8Homo sapiens (human)IC50 (µMol)0.00130.00130.70995.0000AID1853759
Proteasome subunit beta type-7Homo sapiens (human)IC50 (µMol)0.00130.00130.68435.0000AID1853759
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (53)

Processvia Protein(s)Taxonomy
proteolysisProteasome subunit beta type-11Homo sapiens (human)
T cell differentiation in thymusProteasome subunit beta type-11Homo sapiens (human)
CD8-positive, alpha-beta T cell differentiationProteasome subunit beta type-11Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-11Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-7Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-1Homo sapiens (human)
proteolysis involved in protein catabolic processProteasome subunit beta type-1Homo sapiens (human)
immune system processProteasome subunit alpha type-1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusProteasome subunit alpha type-1Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-1Homo sapiens (human)
response to virusProteasome subunit alpha type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-3Homo sapiens (human)
regulation of endopeptidase activityProteasome subunit alpha type-3Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-4Homo sapiens (human)
antigen processing and presentationProteasome subunit beta type-8Homo sapiens (human)
fat cell differentiationProteasome subunit beta type-8Homo sapiens (human)
regulation of endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-8Homo sapiens (human)
immune system processProteasome subunit beta type-9Homo sapiens (human)
regulation of cysteine-type endopeptidase activityProteasome subunit beta type-9Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-9Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-5Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusProteasome subunit beta type-4Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-4Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-6Homo sapiens (human)
proteolysisProteasome subunit beta type-5Homo sapiens (human)
response to oxidative stressProteasome subunit beta type-5Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-5Homo sapiens (human)
cell morphogenesisProteasome subunit beta type-10Homo sapiens (human)
humoral immune responseProteasome subunit beta type-10Homo sapiens (human)
T cell proliferationProteasome subunit beta type-10Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-10Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-3Homo sapiens (human)
response to organonitrogen compoundProteasome subunit beta type-2Homo sapiens (human)
response to organic cyclic compoundProteasome subunit beta type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-6Homo sapiens (human)
regulation of inflammatory responseProteasome subunit alpha type-6Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProteasome subunit alpha type-6Homo sapiens (human)
proteolysis involved in protein catabolic processProteasome subunit alpha type-6Homo sapiens (human)
spermatogenesisProteasome subunit alpha-type 8Homo sapiens (human)
proteasomal protein catabolic processProteasome subunit alpha-type 8Homo sapiens (human)
cell differentiationProteasome subunit alpha-type 8Homo sapiens (human)
meiotic cell cycleProteasome subunit alpha-type 8Homo sapiens (human)
regulation of meiosis IProteasome subunit alpha-type 8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha-type 8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
threonine-type endopeptidase activityProteasome subunit beta type-11Homo sapiens (human)
protein bindingProteasome subunit beta type-11Homo sapiens (human)
peptidase activityProteasome subunit beta type-11Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-11Homo sapiens (human)
protein bindingProteasome subunit alpha type-7Homo sapiens (human)
identical protein bindingProteasome subunit alpha type-7Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
protein bindingProteasome subunit beta type-1Homo sapiens (human)
lipopolysaccharide bindingProteasome subunit alpha type-1Homo sapiens (human)
protein bindingProteasome subunit alpha type-1Homo sapiens (human)
protein bindingProteasome subunit alpha type-2Homo sapiens (human)
protein bindingProteasome subunit alpha type-3Homo sapiens (human)
ubiquitin protein ligase bindingProteasome subunit alpha type-3Homo sapiens (human)
protein bindingProteasome subunit alpha type-4Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
protein bindingProteasome subunit beta type-8Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-9Homo sapiens (human)
protein bindingProteasome subunit beta type-9Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-9Homo sapiens (human)
protein bindingProteasome subunit alpha type-5Homo sapiens (human)
lipopolysaccharide bindingProteasome subunit beta type-4Homo sapiens (human)
protein bindingProteasome subunit beta type-4Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-6Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-6Homo sapiens (human)
protein bindingProteasome subunit beta type-6Homo sapiens (human)
cadherin bindingProteasome subunit beta type-6Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
protein bindingProteasome subunit beta type-5Homo sapiens (human)
peptidase activityProteasome subunit beta type-5Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-10Homo sapiens (human)
protein bindingProteasome subunit beta type-10Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-10Homo sapiens (human)
protein bindingProteasome subunit beta type-3Homo sapiens (human)
protein bindingProteasome subunit beta type-2Homo sapiens (human)
RNA bindingProteasome subunit alpha type-6Homo sapiens (human)
endopeptidase activityProteasome subunit alpha type-6Homo sapiens (human)
protein bindingProteasome subunit alpha type-6Homo sapiens (human)
purine ribonucleoside triphosphate bindingProteasome subunit alpha type-6Homo sapiens (human)
NF-kappaB bindingProteasome subunit alpha type-6Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-7Homo sapiens (human)
protein bindingProteasome subunit beta type-7Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
cytosolProteasome subunit beta type-11Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-11Homo sapiens (human)
nucleusProteasome subunit beta type-11Homo sapiens (human)
cytosolProteasome subunit beta type-11Homo sapiens (human)
nucleusProteasome subunit alpha type-7Homo sapiens (human)
cytoplasmProteasome subunit alpha type-7Homo sapiens (human)
proteasome complexProteasome subunit alpha type-7Homo sapiens (human)
nucleusProteasome subunit alpha type-7Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-7Homo sapiens (human)
cytosolProteasome subunit alpha type-7Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-7Homo sapiens (human)
postsynapseProteasome subunit alpha type-7Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-7Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-7Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nucleusProteasome subunit beta type-1Homo sapiens (human)
cytoplasmProteasome subunit beta type-1Homo sapiens (human)
proteasome complexProteasome subunit beta type-1Homo sapiens (human)
extracellular regionProteasome subunit beta type-1Homo sapiens (human)
nucleusProteasome subunit beta type-1Homo sapiens (human)
nucleoplasmProteasome subunit beta type-1Homo sapiens (human)
cytosolProteasome subunit beta type-1Homo sapiens (human)
secretory granule lumenProteasome subunit beta type-1Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-1Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit beta type-1Homo sapiens (human)
proteasome core complexProteasome subunit beta type-1Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-1Homo sapiens (human)
nucleusProteasome subunit alpha type-1Homo sapiens (human)
cytoplasmProteasome subunit alpha type-1Homo sapiens (human)
proteasome complexProteasome subunit alpha type-1Homo sapiens (human)
nucleusProteasome subunit alpha type-1Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-1Homo sapiens (human)
centrosomeProteasome subunit alpha type-1Homo sapiens (human)
cytosolProteasome subunit alpha type-1Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-1Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-1Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-1Homo sapiens (human)
nucleusProteasome subunit alpha type-2Homo sapiens (human)
cytoplasmProteasome subunit alpha type-2Homo sapiens (human)
proteasome complexProteasome subunit alpha type-2Homo sapiens (human)
P-bodyProteasome subunit alpha type-2Homo sapiens (human)
extracellular regionProteasome subunit alpha type-2Homo sapiens (human)
nucleusProteasome subunit alpha type-2Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-2Homo sapiens (human)
cytosolProteasome subunit alpha type-2Homo sapiens (human)
secretory granule lumenProteasome subunit alpha type-2Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-2Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit alpha type-2Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-2Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-2Homo sapiens (human)
nucleusProteasome subunit alpha type-3Homo sapiens (human)
cytoplasmProteasome subunit alpha type-3Homo sapiens (human)
proteasome complexProteasome subunit alpha type-3Homo sapiens (human)
nucleusProteasome subunit alpha type-3Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-3Homo sapiens (human)
cytoplasmProteasome subunit alpha type-3Homo sapiens (human)
cytosolProteasome subunit alpha type-3Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-3Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-3Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-3Homo sapiens (human)
synapseProteasome subunit alpha type-3Homo sapiens (human)
nucleusProteasome subunit alpha type-4Homo sapiens (human)
cytoplasmProteasome subunit alpha type-4Homo sapiens (human)
proteasome complexProteasome subunit alpha type-4Homo sapiens (human)
P-bodyProteasome subunit alpha type-4Homo sapiens (human)
nucleusProteasome subunit alpha type-4Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-4Homo sapiens (human)
cytosolProteasome subunit alpha type-4Homo sapiens (human)
intracellular membrane-bounded organelleProteasome subunit alpha type-4Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-4Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-4Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-4Homo sapiens (human)
cytosolProteasome subunit alpha type-4Homo sapiens (human)
nucleoplasmProteasome subunit beta type-8Homo sapiens (human)
cytosolProteasome subunit beta type-8Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-8Homo sapiens (human)
proteasome complexProteasome subunit beta type-8Homo sapiens (human)
proteasome core complexProteasome subunit beta type-8Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-8Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-8Homo sapiens (human)
nucleusProteasome subunit beta type-8Homo sapiens (human)
cytosolProteasome subunit beta type-8Homo sapiens (human)
nucleoplasmProteasome subunit beta type-9Homo sapiens (human)
cytosolProteasome subunit beta type-9Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-9Homo sapiens (human)
proteasome complexProteasome subunit beta type-9Homo sapiens (human)
proteasome core complexProteasome subunit beta type-9Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-9Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-9Homo sapiens (human)
cytosolProteasome subunit beta type-9Homo sapiens (human)
nucleusProteasome subunit beta type-9Homo sapiens (human)
nucleusProteasome subunit alpha type-5Homo sapiens (human)
cytoplasmProteasome subunit alpha type-5Homo sapiens (human)
proteasome complexProteasome subunit alpha type-5Homo sapiens (human)
extracellular regionProteasome subunit alpha type-5Homo sapiens (human)
nucleusProteasome subunit alpha type-5Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-5Homo sapiens (human)
cytosolProteasome subunit alpha type-5Homo sapiens (human)
secretory granule lumenProteasome subunit alpha type-5Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-5Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit alpha type-5Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-5Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-5Homo sapiens (human)
nucleusProteasome subunit beta type-4Homo sapiens (human)
cytoplasmProteasome subunit beta type-4Homo sapiens (human)
proteasome complexProteasome subunit beta type-4Homo sapiens (human)
nucleusProteasome subunit beta type-4Homo sapiens (human)
nucleoplasmProteasome subunit beta type-4Homo sapiens (human)
mitochondrionProteasome subunit beta type-4Homo sapiens (human)
cytosolProteasome subunit beta type-4Homo sapiens (human)
ciliary basal bodyProteasome subunit beta type-4Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-4Homo sapiens (human)
proteasome core complexProteasome subunit beta type-4Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-4Homo sapiens (human)
cytosolProteasome subunit beta type-4Homo sapiens (human)
nucleusProteasome subunit beta type-6Homo sapiens (human)
cytoplasmProteasome subunit beta type-6Homo sapiens (human)
proteasome complexProteasome subunit beta type-6Homo sapiens (human)
nucleusProteasome subunit beta type-6Homo sapiens (human)
nucleoplasmProteasome subunit beta type-6Homo sapiens (human)
mitochondrionProteasome subunit beta type-6Homo sapiens (human)
cytosolProteasome subunit beta type-6Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-6Homo sapiens (human)
proteasome core complexProteasome subunit beta type-6Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-6Homo sapiens (human)
cytosolProteasome subunit beta type-6Homo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
cytoplasmProteasome subunit beta type-5Homo sapiens (human)
proteasome complexProteasome subunit beta type-5Homo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
nucleoplasmProteasome subunit beta type-5Homo sapiens (human)
centrosomeProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-5Homo sapiens (human)
proteasome core complexProteasome subunit beta type-5Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
nucleoplasmProteasome subunit beta type-10Homo sapiens (human)
cytosolProteasome subunit beta type-10Homo sapiens (human)
proteasome complexProteasome subunit beta type-10Homo sapiens (human)
proteasome core complexProteasome subunit beta type-10Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-10Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-10Homo sapiens (human)
cytosolProteasome subunit beta type-10Homo sapiens (human)
nucleusProteasome subunit beta type-10Homo sapiens (human)
nucleusProteasome subunit beta type-3Homo sapiens (human)
cytoplasmProteasome subunit beta type-3Homo sapiens (human)
proteasome complexProteasome subunit beta type-3Homo sapiens (human)
nucleusProteasome subunit beta type-3Homo sapiens (human)
nucleoplasmProteasome subunit beta type-3Homo sapiens (human)
cytosolProteasome subunit beta type-3Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-3Homo sapiens (human)
proteasome core complexProteasome subunit beta type-3Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-3Homo sapiens (human)
cytosolProteasome subunit beta type-3Homo sapiens (human)
nucleusProteasome subunit beta type-2Homo sapiens (human)
cytoplasmProteasome subunit beta type-2Homo sapiens (human)
proteasome complexProteasome subunit beta type-2Homo sapiens (human)
nucleusProteasome subunit beta type-2Homo sapiens (human)
nucleoplasmProteasome subunit beta type-2Homo sapiens (human)
cytosolProteasome subunit beta type-2Homo sapiens (human)
membraneProteasome subunit beta type-2Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-2Homo sapiens (human)
proteasome core complexProteasome subunit beta type-2Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-2Homo sapiens (human)
cytosolProteasome subunit beta type-2Homo sapiens (human)
nucleusProteasome subunit alpha type-6Homo sapiens (human)
cytoplasmProteasome subunit alpha type-6Homo sapiens (human)
proteasome complexProteasome subunit alpha type-6Homo sapiens (human)
P-bodyProteasome subunit alpha type-6Homo sapiens (human)
nucleusProteasome subunit alpha type-6Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-6Homo sapiens (human)
cytosolProteasome subunit alpha type-6Homo sapiens (human)
ribosomeProteasome subunit alpha type-6Homo sapiens (human)
nuclear matrixProteasome subunit alpha type-6Homo sapiens (human)
myofibrilProteasome subunit alpha type-6Homo sapiens (human)
sarcomereProteasome subunit alpha type-6Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-6Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-6Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-6Homo sapiens (human)
nucleusProteasome subunit alpha-type 8Homo sapiens (human)
cytosolProteasome subunit alpha-type 8Homo sapiens (human)
extracellular exosomeProteasome subunit alpha-type 8Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha-type 8Homo sapiens (human)
spermatoproteasome complexProteasome subunit alpha-type 8Homo sapiens (human)
nucleusProteasome subunit alpha-type 8Homo sapiens (human)
nucleusProteasome subunit beta type-7Homo sapiens (human)
cytoplasmProteasome subunit beta type-7Homo sapiens (human)
proteasome complexProteasome subunit beta type-7Homo sapiens (human)
extracellular regionProteasome subunit beta type-7Homo sapiens (human)
nucleusProteasome subunit beta type-7Homo sapiens (human)
nucleoplasmProteasome subunit beta type-7Homo sapiens (human)
cytosolProteasome subunit beta type-7Homo sapiens (human)
nuclear bodyProteasome subunit beta type-7Homo sapiens (human)
secretory granule lumenProteasome subunit beta type-7Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit beta type-7Homo sapiens (human)
proteasome core complexProteasome subunit beta type-7Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-7Homo sapiens (human)
cytosolProteasome subunit beta type-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (67)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID745061Inhibition of caspase-like activity of 20S proteasome in rabbit erythrocytes using Z-LLE-betaNA as substrate preincubated for 15 mins measured after 45 mins by fluorescence assay2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
C1 and N5 derivatives of cerpegin: synthesis of a new series based on structure-activity relationships to optimize their inhibitory effect on 20S proteasome.
AID1853756Cytotoxicity against human HOP-92 cells assessed as cell growth inhibition2022European journal of medicinal chemistry, Feb-15, Volume: 230Natural products from mangrove sediments-derived microbes: Structural diversity, bioactivities, biosynthesis, and total synthesis.
AID513336Inhibition of 20S proteasome2006Nature chemical biology, Dec, Volume: 2, Issue:12
Developing a new resource for drug discovery: marine actinomycete bacteria.
AID421802Inhibition of caspase-like activity of rabbit 20S proteasome2009Journal of natural products, Feb-27, Volume: 72, Issue:2
Antiprotealide is a natural product.
AID1853755Cytotoxicity against human LOX IMVI cells assessed as cell growth inhibition2022European journal of medicinal chemistry, Feb-15, Volume: 230Natural products from mangrove sediments-derived microbes: Structural diversity, bioactivities, biosynthesis, and total synthesis.
AID390513Inhibition of chymotrypsin-like activity of human 20S proteasome assessed as enzyme activity recovery 12 hrs after dialysis2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID472366Cytotoxicity against human HCT116 cells after 72 hrs by MTS/PMS assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica.
AID421803Cytotoxicity against human RPMI8226 cells after 48 hrs by resazurin assay2009Journal of natural products, Feb-27, Volume: 72, Issue:2
Antiprotealide is a natural product.
AID1059477Inhibition of human 20S proteasome beta 5 subunit assessed as non-cyclized product formation after 5 to 10 mins by FT-MS analysis2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
(S)-4-Trimethylsilyl-3-butyn-2-ol as an auxiliary for stereocontrolled synthesis of salinosporamide analogs with modifications at positions C2 and C5.
AID240482Inhibition of NF-kB activation in HEK293 cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor.
AID1604182Inhibition of 20S proteasome beta 1c (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID390498Inhibition of chymotrypsin-like activity of rabbit 20S proteasome2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390509Inhibition of trypsin-like activity of rabbit 20S proteasome assessed as enzyme activity recovery 24 hrs after dialysis2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390499Inhibition of trypsin-like activity of rabbit 20S proteasome2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID1853758Cytotoxicity against human PC-3 cells assessed as cell growth inhibition2022European journal of medicinal chemistry, Feb-15, Volume: 230Natural products from mangrove sediments-derived microbes: Structural diversity, bioactivities, biosynthesis, and total synthesis.
AID1604184Inhibition of 20S proteasome beta 2c (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID390506Inhibition of caspase-like activity of human 20S proteasome2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390507Inhibition of chymotrypsin-like activity of rabbit 20S proteasome assessed as enzyme activity recovery 24 hrs after dialysis2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID1604186Inhibition of 20S proteasome beta 5c (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID240557Inhibition of chymotrypsin-like (CT-L) activity of rabbit 20S proteasome2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor.
AID1853759Inhibition of 20S proteasome (unknown origin) by fluorescence based assay2022European journal of medicinal chemistry, Feb-15, Volume: 230Natural products from mangrove sediments-derived microbes: Structural diversity, bioactivities, biosynthesis, and total synthesis.
AID240539Inhibition of trypsin-like (T-L) activity of rabbit 20S proteasome2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor.
AID1059474Inhibition of human 20S proteasome beta 5 subunit assessed as cyclized acylated protein adduct formation after <20 mins by ESI-TOF analysis2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
(S)-4-Trimethylsilyl-3-butyn-2-ol as an auxiliary for stereocontrolled synthesis of salinosporamide analogs with modifications at positions C2 and C5.
AID390503Inhibition of caspase-like activity of yeast 20S proteasome2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID240556Inhibition of caspase-like (CA-L) activity of rabbit 20S proteasome2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor.
AID1076297Inhibition of 20s constitutive proteasome beta 5 subunit chymotrypsin-like activity in rabbit erythrocytes using Suc-LLVY-AMC as substrate incubated for 15 mins prior to substrate addition measured after 45 mins by fluorescence assay2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
New C(4)- and C(1)-derivatives of furo[3,4-c]pyridine-3-ones and related compounds: evidence for site-specific inhibition of the constitutive proteasome and its immunoisoform.
AID395916Cytotoxicity against human HCT116 cells2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Discovery and development of the anticancer agent salinosporamide A (NPI-0052).
AID1076291Inhibition of 20s constitutive proteasome beta 1 subunit caspase-like activity in rabbit erythrocytes using Z-LLE-betaNA as substrate incubated for 15 mins prior to substrate addition measured after 45 mins by fluorescence assay2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
New C(4)- and C(1)-derivatives of furo[3,4-c]pyridine-3-ones and related compounds: evidence for site-specific inhibition of the constitutive proteasome and its immunoisoform.
AID1853757Cytotoxicity against human OVCAR-3 cells assessed as cell growth inhibition2022European journal of medicinal chemistry, Feb-15, Volume: 230Natural products from mangrove sediments-derived microbes: Structural diversity, bioactivities, biosynthesis, and total synthesis.
AID390504Inhibition of chymotrypsin-like activity of human 20S proteasome2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID748896Antiplasmodial activity against Plasmodium falciparum by SYBR Green staining-based fluorescence assay2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Recent advances in malaria drug discovery.
AID1059478Inhibition of chymotrypsin like activity of 20S proteasome in HEK293 cells after 24 hrs by microscopic analysis2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
(S)-4-Trimethylsilyl-3-butyn-2-ol as an auxiliary for stereocontrolled synthesis of salinosporamide analogs with modifications at positions C2 and C5.
AID1059479Inhibition of chymotrypsin like activity of human 20S proteasome after 1 hr by luminescence assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
(S)-4-Trimethylsilyl-3-butyn-2-ol as an auxiliary for stereocontrolled synthesis of salinosporamide analogs with modifications at positions C2 and C5.
AID390500Inhibition of caspase-like activity of rabbit 20S proteasome2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390517Inhibition of trypsin-like activity of human 20S proteasome assessed as release of free AMC substrate by fluorimetry based kinetic assay2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390518Inhibition of caspase-like activity of human 20S proteasome assessed as release of free AMC substrate by fluorimetry based kinetic assay2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID628579Irreversible inhibition of 20S proteasome2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Highlights of marine invertebrate-derived biosynthetic products: their biomedical potential and possible production by microbial associants.
AID745063Inhibition of chymotrypsin-like activity of 20S proteasome in rabbit erythrocytes using Suc-LLVY-AMC as substrate preincubated for 15 mins measured after 45 mins by fluorescence assay2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
C1 and N5 derivatives of cerpegin: synthesis of a new series based on structure-activity relationships to optimize their inhibitory effect on 20S proteasome.
AID421801Inhibition of trypsin-like activity of rabbit 20S proteasome2009Journal of natural products, Feb-27, Volume: 72, Issue:2
Antiprotealide is a natural product.
AID472365Inhibition of chymotrypsin like activity of yeast 20S proteasome beta 5 subunit after 30 mins by fluorescence assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica.
AID390501Inhibition of chymotrypsin-like activity of yeast 20S proteasome2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390514Inhibition of trypsin-like activity of human 20S proteasome assessed as enzyme activity recovery 12 hrs after dialysis2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390521Inhibition of caspase-like activity of human 20S proteasome assessed as inactivation rate by fluorimetry based kinetic assay2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID748895Antimalarial activity against Plasmodium yoelii yoelii infected in mouse2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Recent advances in malaria drug discovery.
AID706738Reversible inhibition of human erythrocyte derived 20S proteasome subunit beta5 after 30 mins by fluorogenic assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Molecular mechanisms of acquired proteasome inhibitor resistance.
AID390519Inhibition of chymotrypsin-like activity of human 20S proteasome assessed as inactivation rate by fluorimetry based kinetic assay2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID628580Cytotoxicity against human HCT116 cells2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Highlights of marine invertebrate-derived biosynthetic products: their biomedical potential and possible production by microbial associants.
AID395917Cytotoxicity against human NCI60 cells2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Discovery and development of the anticancer agent salinosporamide A (NPI-0052).
AID390515Inhibition of caspase-like activity of human 20S proteasome assessed as enzyme activity recovery 12 hrs after dialysis2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID421800Inhibition of chymotrypsin-like activity of rabbit 20S proteasome2009Journal of natural products, Feb-27, Volume: 72, Issue:2
Antiprotealide is a natural product.
AID1059476Inhibition of human 20S proteasome beta 5 subunit assessed as non-cyclized product formation after 5 to 10 mins by ESI-TOF analysis2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
(S)-4-Trimethylsilyl-3-butyn-2-ol as an auxiliary for stereocontrolled synthesis of salinosporamide analogs with modifications at positions C2 and C5.
AID706736Reversible inhibition of human erythrocyte derived 20S proteasome subunit beta1 after 30 mins by fluorogenic assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Molecular mechanisms of acquired proteasome inhibitor resistance.
AID1059475Inhibition of human 20S proteasome beta 5 subunit assessed as cyclized acylated protein adduct formation after <20 mins by FT-MS analysis2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
(S)-4-Trimethylsilyl-3-butyn-2-ol as an auxiliary for stereocontrolled synthesis of salinosporamide analogs with modifications at positions C2 and C5.
AID390510Inhibition of caspase-like activity of rabbit 20S proteasome assessed as enzyme activity recovery 24 hrs after dialysis2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID745062Inhibition of trypsin-like activity of 20S proteasome in rabbit erythrocytes using Boc-LRR-AMC as substrate preincubated for 15 mins measured after 45 mins by fluorescence assay2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
C1 and N5 derivatives of cerpegin: synthesis of a new series based on structure-activity relationships to optimize their inhibitory effect on 20S proteasome.
AID1853754Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition2022European journal of medicinal chemistry, Feb-15, Volume: 230Natural products from mangrove sediments-derived microbes: Structural diversity, bioactivities, biosynthesis, and total synthesis.
AID390520Inhibition of trypsin-like activity of human 20S proteasome assessed as inactivation rate by fluorimetry based kinetic assay2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID706737Reversible inhibition of human erythrocyte derived 20S proteasome subunit beta2 after 30 mins by fluorogenic assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Molecular mechanisms of acquired proteasome inhibitor resistance.
AID247472Cytotoxic activity against RPMI 8226 cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor.
AID390505Inhibition of trypsin-like activity of human 20S proteasome2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390502Inhibition of trypsin-like activity of yeast 20S proteasome2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID1076294Inhibition of 20s constitutive proteasome beta 2 subunit trypsin-like activity in rabbit erythrocytes using Boc-LRR-AMC as substrate incubated for 15 mins prior to substrate addition measured after 45 mins by fluorescence assay2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
New C(4)- and C(1)-derivatives of furo[3,4-c]pyridine-3-ones and related compounds: evidence for site-specific inhibition of the constitutive proteasome and its immunoisoform.
AID390497Stability in 20 mM HEPES buffer assessed as beta-lactone hydrolysis rate at pH 7.3 at 27 degC2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390516Inhibition of chymotrypsin-like activity of human 20S proteasome assessed as release of free AMC substrate by fluorimetry based kinetic assay2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID734743Half life in TEAA buffer at pH 7.4 by HPLC analysis2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of Belactosin A: synthesis, biological activity, and mode of action.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (127)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's56 (44.09)29.6817
2010's62 (48.82)24.3611
2020's9 (7.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.81 (24.57)
Research Supply Index4.88 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index50.33 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (3.15%)5.53%
Reviews29 (22.83%)6.00%
Case Studies1 (0.79%)4.05%
Observational0 (0.00%)0.25%
Other93 (73.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]